Spanish food company Natraceutical has bought UK rival Braes Group for €80m (US$102.1m) as the first step in its international expansion strategy which includes the acquisition of complementary businesses.
Go deeper with GlobalData
Valencia-based Natraceutical bought the firm from British private equity group 3i. It plans to finance the deal with its own cash flow and through an undisclosed share offer.
London-based Braes owns the Swiss-based biotech concerns Obipektin and Spreda as well as Overseal, a UK-based concern that makes sweetener Talin.
Natraceutical also named Xavier Adsera its new president, replacing Vicente Dominguez who resigned from the post. Natraceutical posted a 7.7% jump to €904,000 in first-quarter net profits on flat revenues of €5.8m, boosted by higher operating margins.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
